BridgeBio Pharma, Inc.
BBIO· Nasdaq
BBIOBridgeBio Pharma, Inc.
Filed Nov 8, 2019 · 10-Q · 39 days after period end · 0001564590-19-041986
| Metric | Q3 2019 | Q3 2018 |
|---|---|---|
| Revenue | $26.74M | — |
| Net Income | -$60.66M | -$42.08M |
| EPS Diluted | -$0.51 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end
